title: Microglial activation and neurological symptoms in the SIV model of NeuroAIDS: association of MHC-II and MMP-9 expression with behavioral deficits and evoked potential changes.
abstract: HIV-1 causes cognitive and motor deficits and HIV encephalitis (HIVE) in a significant proportion of AIDS patients. Neurological impairment and HIVE are thought to result from release of cytokines and other harmful substances from infected, activated microglia. In this study, the quantitative relationship between microglial activation and neurological impairment was examined in the simian immunodeficiency model of HIVE. Macaque monkeys were infected with a passaged, neurovirulent strain of simian immunodeficiency virus, SIV(mac)239(R71/17E). In concurrent studies, functional impairment was assessed by motor and auditory brainstem evoked potentials and by measurements of cognitive and motor behavioral deficits. Brain tissue was examined by immunohistochemistry using two markers of microglia activation, MHC-II and matrix metalloproteinase-9 (MMP-9). The inoculated animals formed two groups: rapid progressors, which survived 6-14 weeks postinoculation, and slow progressors, which survived 87-109 weeks. In the rapid progressors, two patterns of MHC-II expression were present: (1) a widely disseminated pattern of MHC-II expressing microglia and microglial nodules in cortical gray matter and subcortical white matter, and (2) a more focal pattern in which MHC-II expressing microglia were concentrated into white matter. Animals exhibiting both patterns of microglial activation showed mild to severe changes in cognitive and motor behavior and evoked potentials. All rapid progressors showed expression of MMP-9 in microglia located in subcortical white matter. In the slow progressors MHC-II and MMP-9 staining was similar to uninoculated control macaques, and there was little or no evidence of HIVE. These animals showed behavioral deficits at the end of the disease course, but little changes in evoked potentials. Thus, increases in MHC-II and MMP-9 expression are associated with development of cognitive and motor deficits, alterations in evoked potentials, and rapid disease progression.
authors.affiliation: Department of Anatomy and Cell Biology, Marion Merrell Dow Laboratories, Kansas City, KS 66160-7400, USA.
authors.forename: N E
authors.initials: NE
authors.lastname: Berman
authors.forename: J K
authors.initials: JK
authors.lastname: Marcario
authors.forename: C
authors.initials: C
authors.lastname: Yong
authors.forename: R
authors.initials: R
authors.lastname: Raghavan
authors.forename: L A
authors.initials: LA
authors.lastname: Raymond
authors.forename: S V
authors.initials: SV
authors.lastname: Joag
authors.forename: O
authors.initials: O
authors.lastname: Narayan
authors.forename: P D
authors.initials: PD
authors.lastname: Cheney
mesh_terms: D015526:AIDS Dementia Complex / Q000097:blood / Q000134:cerebrospinal fluid / Q000503:physiopathology*; D000818:Animals; D001522:Behavior, Animal / Q000502:physiology*; D003071:Cognition / Q000502:physiology; D004195:Disease Models, Animal; D005071:Evoked Potentials / Q000502:physiology*; D000949:Histocompatibility Antigens Class II / Q000378:metabolism*; D008253:Macaca mulatta; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D017628:Microglia / Q000378:metabolism* / Q000821:virology*; D009043:Motor Activity / Q000502:physiology; D015301:Retroviruses, Simian / Q000502:physiology*; D013647:Task Performance and Analysis
chemical_list: D000949:Histocompatibility Antigens Class II; D020780:Matrix Metalloproteinase 9